Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary

Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage biotech company, has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules, raising $8 million in gross proceeds. The offering included 2,465,000 shares of common stock or pre-funded warrants, along with warrants to purchase up to 12,325,000 shares at $3.25 per share. Each common stock share comes with five Common Warrants exercisable upon stockholder approval, with a five-year expiration term. Roth Capital Partners served as the placement agent. The company plans to use the proceeds for clinical development of its product candidates, working capital, and general corporate purposes.

Positive

• Secured $8 million in gross proceeds to support operations and development
• Warrants provide potential for additional future funding at $3.25 per share
• Funds will support continued clinical development of product candidates

Negative

• Significant dilution potential with warrants for up to 12,325,000 additional shares
• Offering requires stockholder approval for warrant exercise
• At-the-market pricing indicates potential pressure on stock value

Insights

Biotech Investment Analyst

Aptevo secured $8M in dilutive financing with significant warrant coverage, addressing immediate cash needs while substantially diluting shareholders.

Aptevo Therapeutics has closed an $8 million registered direct offering priced at-the-market. The structure of this financing is particularly notable - each $3.25 share comes bundled with five warrants (also at $3.25), creating potential for significant future dilution. The company issued approximately 2.47 million shares with warrants for an additional 12.33 million shares, representing substantial dilution potential of about 5x the initial share issuance.

This financing appears designed to address immediate capital needs for Aptevo's clinical-stage immune-oncology pipeline based on their proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms. The warrant structure suggests investors required significant upside potential to participate, indicating challenging fundraising conditions for the company. The at-the-market pricing avoids the discount typically seen in more distressed offerings, but the extensive warrant coverage effectively compensates investors for the risk.

For existing shareholders, this transaction has contradictory implications. While it provides essential working capital to advance clinical programs, the potential dilution from warrant exercise could significantly impact ownership percentages. The requirement for stockholder approval before warrant exercise suggests the potential dilution exceeds current authorized share limits. Roth Capital's involvement as placement agent lends some credibility to the transaction, but the overall structure indicates Aptevo faced limited financing options during this capital raise.

SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 2,465,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 12,325,000 shares of its common stock (the "Common Warrants") at a purchase price of $3.25 per share and associated Common Warrants in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with five Common Warrants, each to purchase one share of common stock. The Common Warrants have an exercise price of $3.25 per share, are exercisable upon stockholder approval, and will expire five years following the date stockholder approval.

Roth Capital Partners is acted as placement agent of the offering. Gross proceeds, before deducting placement agent fees and commissions and offering expenses, were approximately $8 million. The company intends to use the net proceeds from the offering for the continued clinical development of its product candidates, working capital, and other general corporate purposes.

The securities described above were offered pursuant to registration statements on Form S-1 (File No. 333-288061), that was declared effective by the U.S. Securities and Exchange Commission ("SEC"), on June 18, 2025 and on and form S-1MEF (File No. 333-288134), that was declared effective immediately upon filing on June 18, 2025. The offering was made solely by means of a prospectus. Copies of the accompanying prospectus relating to and describing the terms of the offering may be obtained at the SEC's website at www.sec.gov or by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660 or by email at rothecm@roth.com. This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. All offers were made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for the treatment of cancer. Aptevo is seeking to improve treatment outcomes of cancer patients. For more information, please visit www.aptevotherapeutics.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, statements regarding the use of proceeds of the offering, Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of its therapeutic candidates and potential use of any such candidates, including in combination with other drugs, as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, statements related to the progress of Aptevo's clinical programs, including statements related to anticipated clinical and regulatory milestones, whether further study of mipletamig in a Phase 1b dose optimization trial focusing on multiple doses of mipletamig in combination with venetoclax + azacitidine on a targeted patient population will continue to show remissions, whether Aptevo's final remission data or trial results will vary from its earlier assessment, whether Aptevo's strategy will translate into an improved overall survival in AML, especially among patient subgroups with poor prognosis, whether further study of ALG.APV-527 across multiple tumor types will continue to show clinical benefit, the possibility and timing of future preliminary or interim data readouts for ALG.APV-527, statements related to the progress of and enthusiasm for Aptevo's clinical programs, statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words "may," "continue to," "believes," "knows," "expects," "optimism," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.

There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the results of preliminary or interim data and preclinical studies being predictive of the results of later-stage clinical trials, initiation, enrollment and maintenance of patients, and the completion of clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of Aptevo's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises, geopolitical risks, including the current wars between Russia and Ukraine, Israel and Hamas, Israel and Iran, and any other military event that could evolve out of any of the current conflicts and macroeconomic conditions such as economic uncertainty, imposition of tariffs, rising inflation and interest rates, continued market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.

CONTACT:
Miriam Weber Miller
Head, Investor Relations & Corporate Communications
Aptevo Therapeutics
Email: IR@apvo.com or Millerm@apvo.co
Phone: 206-859-6628

SOURCE: Aptevo Therapeutics

View the original press release on ACCESS Newswire

FAQ

How much did Aptevo Therapeutics (APVO) raise in their June 2025 offering?

Aptevo Therapeutics raised $8 million in gross proceeds through a registered direct offering priced at-the-market under Nasdaq rules.

What is the exercise price of APVO's Common Warrants in the June 2025 offering?

The Common Warrants have an exercise price of $3.25 per share and will expire five years after receiving stockholder approval.

How many shares and warrants were included in APVO's June 2025 offering?

The offering included 2,465,000 shares of common stock or pre-funded warrants, plus warrants to purchase up to 12,325,000 shares of common stock.

What will Aptevo Therapeutics use the proceeds for?

Aptevo plans to use the net proceeds for continued clinical development of its product candidates, working capital, and other general corporate purposes.

Who was the placement agent for APVO's June 2025 offering?

Roth Capital Partners acted as the placement agent for the offering.